Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q4G0A6

UPID:
MINY4_HUMAN

ALTERNATIVE NAMES:
Probable deubiquitinating enzyme MINDY-4

ALTERNATIVE UPACC:
Q4G0A6; Q71AZ7; Q9H6D2

BACKGROUND:
The enzyme Probable ubiquitin carboxyl-terminal hydrolase MINDY-4, alternatively named Probable deubiquitinating enzyme MINDY-4, is implicated in the critical biological process of removing 'Lys-48'-linked ubiquitin from proteins. This action is essential for maintaining cellular homeostasis by regulating protein turnover and signaling pathways, which are fundamental for cell survival, proliferation, and immune defense mechanisms.

THERAPEUTIC SIGNIFICANCE:
The exploration of Probable ubiquitin carboxyl-terminal hydrolase MINDY-4's function offers a promising avenue for drug discovery and therapeutic intervention. By elucidating its role in ubiquitin-mediated processes, researchers can identify novel targets for the treatment of diseases characterized by abnormal protein degradation and signaling.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.